Zymelin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zymelin

What is Zymelin? Defining its Identity and Purpose

Property Description
Active ingredient Xylometazoline hydrochloride
Form Nasal spray or drops (Aqueous solution)
Pharmacological class Local decongestant, Sympathomimetic agent
Common use Relief of nasal congestion
Origin Synthetic, Imidazoline derivative

What is Zymelin and its Composition?

Zymelin is a brand name for a medicinal product specifically designed for topical application in the nose. Its sole active substance is Xylometazoline hydrochloride, a widely utilized synthetic compound that belongs to the imidazoline derivative group. Zymelin is formulated as a single-component product in an aqueous solution. This precise chemical structure and formulation ensure a focused effect, which is clinically recognized for its ability to target localized vascular tissue in the nasal mucosa.


What Pharmacological Class Does Zymelin Belong To?

Zymelin's active component, Xylometazoline, is categorized pharmacologically as a local decongestant and a sympathomimetic agent. This classification confirms its mechanism as an alpha-adrenergic agonist that acts directly on the nasal tissues. The product is delivered via topical nasal administration as a nasal spray or drops, a method chosen to concentrate the action precisely where congestion occurs.


What is the General Purpose of Xylometazoline?

The primary general purpose of Xylometazoline is to provide temporary relief from nasal congestion and obstruction. The active ingredient works through the principle of vasoconstriction, causing the local blood vessels in the nasal mucous membranes to contract. This action confirms that the drug reduces the swelling and inflammation that cause the blocked sensation. By physically shrinking the membranes, the medicine facilitates improved airflow, which provides relief in common scenarios like a severe head cold or seasonal rhinitis.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Zymelin?

Possible Side Effects and Safety Information

The safety profile for Zymelin, which contains Xylometazoline hydrochloride, is defined by localized application effects and the potential for systemic adverse reactions due to its sympathomimetic activity, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

The official labeling classifies adverse reactions according to frequency:

Classification Examples of Documented Effects
Common Stinging or burning sensation in the nose and throat, dry nasal mucous membranes, headache, nausea, burning at the administration site.
Uncommon Hypersensitivity reactions (e.g., rash), epistaxis (nosebleed), increased swelling of nasal mucous membranes upon cessation of treatment.
Rare Palpitations, tachycardia (increased heart rate), hypertension (increased blood pressure).
Very Rare Arrhythmia, nervousness, insomnia, hallucinations, convulsions, apnoea (irregular breathing, in infants/neonates).

Systemic and Duration-Related Safety Concerns

The most frequent effects are generally localized to the Respiratory System. However, the regulatory documentation highlights the risk of Rare or Very Rare systemic effects affecting the Cardiovascular and Nervous Systems, particularly with high systemic absorption.

Of specific note, the safety profile documents the risk of rebound congestion (Rhinitis Medicamentosa). This is associated with prolonged or excessive use, where the nasal swelling may increase after the medicine is stopped.

Population-Specific Safety: Infants and neonates are explicitly noted as being more susceptible to the serious systemic effects of overdose, including CNS depression and apnoea.

Safety Restrictions: Use of the medicine is restricted for individuals with pre-existing conditions such as rhinitis sicca, narrow-angle glaucoma, or those concurrently using Monoamine Oxidase Inhibitors (MAOIs), as detailed in the regulatory contraindications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Xylometazoline hydrochloride (Zymelin), whether due to accidental ingestion or excessive topical administration, is officially documented by regulatory authorities to cause serious systemic effects primarily involving the central nervous system (CNS) and the cardiovascular system (CVS).

Documented manifestations include severe dizziness, headache, profuse perspiration, and consciousness clouding. Severe outcomes listed in official labeling include convulsions, coma, respiratory depression, and significant cardiac effects such as arrhythmias, bradycardia, and tachycardia. Blood pressure changes are notable, often presenting as initial hypertension followed by hypotension. Severely lowered body temperature (hypothermia) has also been reported.

Immediate medical attention must be sought for any suspected overdose. Regulatory guidance explicitly mandates calling a poison control center or a doctor immediately, especially following accidental swallowing. Small children are officially noted to be highly sensitive to the drug’s toxicity, with accidental ingestion in this population leading to serious adverse events that require hospitalization.

Management is strictly symptomatic and supportive, as no specific antidote is known. The official procedure includes initiating appropriate supportive treatment under medical supervision and requires observation and monitoring for several hours.

Therapeutic Uses of Zymelin

What Zymelin Treats: Main Uses and Benefits

Symptomatic Relief and Functional Benefit

Zymelin's active ingredient is used in situations involving certain distressing symptoms of nasal congestion linked to conditions characterized by periods of heightened symptoms, including the common cold, perennial and allergic rhinitis (hay fever), and sinusitis. It is commonly used across conditions presenting with acute episodes, such as those arising from seasonal triggers or viral infections.

The core benefit is applied across domains where additional symptomatic support is needed to manage symptoms that interfere with daily comfort. Zymelin helps address groups of symptoms that may appear suddenly and create noticeable physiological strain, and may be part of symptomatic management during phases when symptoms become more noticeable. This support contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Nasal Obstruction

The functional benefit is particularly valued for easing the impact of congestion on sleep quality and assists with maintaining functional stability. Zymelin provides support that helps ease the overall symptom burden when symptoms become difficult to tolerate, ensuring the information remains patient-friendly and focused solely on therapeutic benefit.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Zymelin (Xylometazoline)

Official regulatory documents define specific populations who are eligible, restricted, or prohibited from using Zymelin, based on age, existing medical conditions, and clinical status.


Absolute Contraindications (Must Not Use)

Use of Zymelin is strictly prohibited in patients with a known hypersensitivity to xylometazoline, narrow-angle glaucoma, rhinitis sicca (atrophic rhinitis), or following trans-sphenoidal hypophysectomy or surgery exposing the dura mater. The medicine is also contraindicated for patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.


Age-Related Eligibility

The 0.1% strength solution is approved for adults and adolescents aged 12 years and over. The 0.05% strength solution is intended for children between 6 and 12 years.

Zymelin is contraindicated in children under 2 years of age, and the 0.1% strength is contraindicated for all children under 12 years.


Restricted or Conditional Use

Use requires special caution and restriction in individuals with certain pre-existing conditions, including severe cardiovascular disease (such as hypertension or long QT syndrome), hyperthyroidism, diabetes mellitus, phaeochromocytoma, and prostatic hypertrophy. Use is not recommended during pregnancy and requires medical advice during lactation due to potential systemic effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Zymelin (Xylometazoline) is primarily defined by the drug's classification as a sympathomimetic agent and its resulting potential for pharmacodynamic potentiation of pressor effects. Regulatory documents establish constraints around combinations that could elevate blood pressure.

Official Interaction Statements

Classification Interacting Substance/Class Official Interaction Description
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to the risk of severe hypertension (hypertensive crisis).
Use with Caution Tricyclic Antidepressants (TCAs) Increased risk of hypertension and arrhythmias due to pressor effect potentiation.
Pharmacodynamic Risk Other Sympathomimetic Agents Additive cardiovascular effects and increased risk of cardiovascular toxicity.
Efficacy Reduction Risk Antihypertensive Agents May reduce the blood pressure-lowering effect of agents like Beta-blockers.

Co-administration with MAOIs is strictly forbidden, and a mandatory separation period of up to 14 days is required after stopping MAOI therapy before Xylometazoline can be administered. This timing rule is mandated to mitigate the risk of a dangerous hypertensive reaction. No clinically relevant pharmacokinetic (CYP-mediated) or food/alcohol interactions are documented in the official regulatory prescribing information for this topical product.

Mechanism of Action

How Zymelin Works

Xylometazoline initiates its action by binding to receptors within the localized vasculature of the nasal passages. The mechanism involves specific molecular interactions that result in a rapid, localized physiological consequence.


Targeting Alpha-Adrenergic Receptors

The drug acts as a direct agonist by binding to and activating alpha-adrenergic receptors (primarily alpha1 and alpha2) located on the smooth muscle lining of the local blood vessels. This interaction initiates a signaling cascade characteristic of the adrenergic nervous system, which regulates vascular tone.


Modulating Local Vascular Tone and Engorgement

The activation of these receptors causes the smooth muscles in the vessel walls to contract, a process termed vasoconstriction. This physiological response restricts the flow of blood into the tissue. The mechanism is relevant in systems where targeted pathway adjustment is required to reduce the volume of blood and fluid entering the tissue, thereby actively contributing to the reduction of blood volume and interstitial fluid within the nasal membranes.

Dosage and Administration Information

Zymelin (Xylometazoline hydrochloride) is a nasal decongestant administered as a spray or drops for the symptomatic relief of nasal congestion caused by rhinitis or sinusitis. It acts as a vasoconstrictor, which helps reduce swelling of the nasal mucous membranes, thus facilitating easier breathing.

Dosage and Administration

The correct usage involves blowing the nose gently before application. If the product is a nasal spray, the pump must be primed by pressing it a few times until a fine mist is ejected before the first use. To administer, the head should be bent slightly forward, and one nostril should be closed with a finger. The spray tip is inserted into the open nostril, and the pump is pressed quickly while inhaling through the nose. The process is then repeated in the other nostril.

Age Group Concentration Dose Frequency Maximum Duration
Adults & Children 10 years and older 1 mg/ml Spray 1 puff in each nostril Maximum 3 times daily 10 days
Children 2-10 years 0.5 mg/ml Spray/Drops 1 puff/drop in each nostril Maximum 3 times daily 5 days

Important Considerations

Do not use Zymelin for longer than the recommended duration, as prolonged or frequent use (typically more than 5 to 10 days) may lead to dependence and a condition known as rebound congestion (chronic rhinitis with increased nasal swelling and hypersecretion). Always adhere strictly to the dosing schedule and do not exceed the maximum daily doses. Sharing the nasal spray container with other individuals is not recommended, as this can lead to the spread of infection.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zymelin (Xylometazoline)

Evidence for Use in Nasal Congestion Associated with the Common Cold

Research has examined the action of Xylometazoline, the active ingredient in Zymelin, using short-term randomized controlled trials (RCTs). These studies were primarily applied in research contexts involving adult populations experiencing acute episodes of congestion and other symptoms of the common cold. Researchers used specialized instruments to monitor changes in objective nasal patency (airflow) and applied in studies examining patient-reported experiences of nasal stuffiness over short, defined time intervals.

The findings derived from these trials and subsequent meta-analyses describe patterns where measured changes in nasal patency were observed over defined time intervals following administration. Research highlights changes measured during the study period for outcomes related to physical discomfort. The evidence remains limited, however, regarding the consequences of use that extends beyond the short, recommended duration. Long-term outcomes are not well characterized by the existing research landscape.


Evidence for Use in Rhinitis-Related Nasal Congestion

Studies also explored the use of Xylometazoline for nasal congestion linked to conditions characterized by fluctuating or episodic manifestations, such as perennial and allergic rhinitis (hay fever). The research examined responses during episodes where symptoms become more noticeable. These trials often included comparative studies where the drug was evaluated against placebo or other nasal treatments in adults presenting with rhinitis.

Studies monitored outcomes related to functional imbalance by measuring changes in nasal airflow. The research reported on acute effects rather than long-term management of the underlying condition. Data for long-term outcomes in chronic rhinitis are still emerging, and comparative evidence is lacking for Xylometazoline when considered as a primary, long-term treatment strategy against other maintenance therapies.


What is Still Uncertain in the Research Landscape

The evidence highlights what is known, but also what is still uncertain about the use of Xylometazoline. A key limitation is the modest sample sizes and limited follow-up durations of many primary trials. The evidence quality varies across studies, and research exploring short-term symptom changes does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. Furthermore, the functional impact on outcomes reflecting daily functioning or activity level in long-term scenarios is not well characterized by existing studies.

Key Studies & References

  1. The efficacy of xylometazoline, the risk of rhinitis medicamentosa (RM), and treatment strategies: A review of published studies
  2. Public Assessment Reports of the Medicines Evaluation Board in the Netherlands: Nasadur 1 mg/ml and 0.5 mg/ml nasal spray, solution (Xylometazoline HCl - Regulatory and Established Use)

Frequently Asked Questions (FAQ)

Common questions about Zymelin (FAQ)

Q: How quickly does Zymelin usually start working?

Regulatory documents indicate that the onset of action is generally rapid, with the local decongestant effect beginning within a few minutes of application. This rapid physiological consequence is due to the drug quickly causing vasoconstriction in the nasal passages.

Q: How long does the effect of one dose of Zymelin last?

According to the official product information for Zymelin (Xylometazoline), the relief provided by a single dose is officially reported to last for up to 10 to 12 hours. Patients are reminded that adherence to the maximum daily frequency and labeled duration is necessary for proper use.

Q: What is Zymelin used for besides the main condition?

Regulatory indications list several accepted uses beyond the common cold and general rhinitis. Xylometazoline is also accepted for the relief of nasal congestion associated with sinusitis and sometimes for conditions like headache, tubal block, and serous otitis media.

Q: Does Zymelin require a prescription in most countries?

Regulatory status generally defines Xylometazoline as a nonprescription product. It is widely authorized as an over-the-counter (OTC) topical nasal decongestant in many countries internationally.

Q: Are there generic versions of Zymelin available?

The active ingredient, Xylometazoline hydrochloride, is widely available globally. Therefore, generic products containing the same active substance are available under various different brand names internationally.

Q: Why do some people experience dry mouth when taking Zymelin?

Dryness of the nasal mucous membranes is a commonly documented side effect of Xylometazoline. This localized drying effect in the nasal area can sometimes be related to or perceived as a sensation of dry mouth.

Q: Can Zymelin cause dizziness or problems with balance?

Dizziness is listed in the official safety profile as a potential systemic side effect that may occur. Any systemic side effects are typically addressed by a healthcare professional.

Q: Is it normal to sweat more while on Zymelin?

Unusual or increased sweating is listed as a potential systemic side effect that may occur. Systemic side effects are typically reported to a healthcare professional.

Q: What happens if I miss a dose of Zymelin?

Official patient information describes guidance for a missed dose, stating that double doses are to be avoided and directing users to adhere to the prescribed frequency. This information is intended to ensure proper administration and prevent exceeding the maximum daily limits.

Q: Can Zymelin be taken by people with kidney issues?

Official regulatory documents list kidney diseases or renal impairment as conditions where the drug must be used with special caution. This cautionary note is based on the potential for systemic absorption.

Q: What is the connection between Zymelin and liver function, as mentioned in forums?

Official regulatory documents list a history of liver diseases or hepatic impairment as conditions where the drug must be used with special caution. This precaution is in place due to the drug's potential for systemic effects.

Q: Is it common for Zymelin to be started at a low dose?

Dosing is standardized based on age and the required concentration (e.g., lower concentration for younger children). The product is not generally structured around a clinical philosophy of starting low and titrating the dose upward for typical adult use.

Q: Is Zymelin safe to use for older adults?

The elderly population is listed in regulatory documents as one for which special caution is advised due to the potential for systemic effects. Adherence to the recommended dosage is noted as necessary for safe use.

Q: Can Zymelin cause weight gain?

Weight gain is not listed as a common, uncommon, or rare side effect in the documented official safety information for this topical medication.

Q: Do people typically feel tired after taking Zymelin?

Official safety documents do not list fatigue or tiredness as a commonly reported side effect. However, nervousness and other central nervous system effects are sometimes reported.

Q: Can Zymelin interact with caffeine or energy drinks?

There is no direct official interaction listed with caffeine. However, due to its sympathomimetic classification, it has the potential for additive cardiovascular effects when used alongside other stimulants.

Q: Does Zymelin contain any common allergens like gluten or lactose?

The active substance is Xylometazoline hydrochloride in an aqueous solution. Regulatory standards recommend checking the full list for specific inactive ingredients like preservatives or known allergens, as these must be listed on the product label.

Q: What kind of research has been done on Zymelin in children?

The established dosing for different pediatric age groups (such as ages 2–12 years) is supported by existing research. This includes clinical trials and pooled analyses that examined the effects of Xylometazoline in children.

Q: Is it okay to take Zymelin with antacids?

Official drug interaction information typically does not list antacids as a known interacting substance with this topical nasal medication.

Q: Does Zymelin interact with hormonal birth control?

No official interaction with hormonal birth control is generally listed in the regulatory interaction statements for Xylometazoline, which is a topical decongestant.

Q: Does Zymelin make you more sensitive to sunlight?

Photosensitivity or increased sensitivity to sunlight is not listed in the documented official side effect profile of Xylometazoline.

Q: Is there any research on Zymelin's use in combination with common allergy medications?

While research has compared Zymelin to other nasal treatments, no official interaction is generally listed for Xylometazoline when used in combination with common systemic allergy medications like antihistamines.

Q: Is Zymelin used in other countries for different conditions than in the US?

The indications for Xylometazoline listed globally are largely consistent. They include relief for nasal congestion due to colds, hay fever, and sinusitis, along with associated conditions like serous otitis media and eustachian tube block.

Q: Can Zymelin be taken with common over-the-counter vitamins or supplements?

Regulatory guidance describes the requirement for healthcare professionals to review all concomitant product use, including over-the-counter medicines, vitamins, or supplements, to check against potential interactions.

Q: Is Zymelin associated with any specific diet or lifestyle changes?

Regulatory documents do not mandate specific dietary changes with the use of Zymelin. However, patient information often mentions general supportive practices like ensuring adequate fluid intake or avoiding known allergen triggers.

How should Zymelin be stored and disposed of?

Storage and Disposal Requirements

The official labeling for Zymelin (xylometazoline hydrochloride) specifies strict conditions to maintain product stability and ensure safety.


Storage Conditions

Requirement Description
Temperature Store at or below 25°C (77°F), typically room temperature.
Protection Keep the container tightly closed and protect the product from light. Do not freeze.
Child Safety Store the medicine out of the sight and reach of children.

Stability and Handling

For hygienic reasons, each spray bottle should only be used by one person. Once the container is first opened, the nasal solution must not be used longer than 28 days. The product must be handled and stored in accordance with these hygienic and stability rules.


Disposal Instructions

Do not dispose of the unused medicine via wastewater or household trash. Dispose of the contents and container in accordance with local, regional, and national regulations, often requiring consultation with a pharmacist or use of an official collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zymelin found in:

A-Z Index: